Inhibrx Biosciences, Inc.
INBX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $200 | $1,800 | $2,192 | $7,125 |
| % Growth | -88.9% | -17.9% | -69.2% | – |
| Cost of Goods Sold | $2,285 | $1,191 | $110,186 | $2,688 |
| Gross Profit | -$2,085 | $609 | -$107,994 | $4,437 |
| % Margin | -1,042.5% | 33.8% | -4,926.7% | 62.3% |
| R&D Expenses | $203,743 | $190,648 | $110,186 | $71,440 |
| G&A Expenses | $127,905 | $29,381 | $21,123 | $12,355 |
| SG&A Expenses | $127,905 | $29,381 | $21,123 | $12,355 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$2,285 | -$199 | -$110,187 | -$71,454 |
| Operating Expenses | $329,363 | $219,830 | $21,122 | $12,341 |
| Operating Income | -$331,448 | -$219,221 | -$129,117 | -$76,564 |
| % Margin | -165,724% | -12,178.9% | -5,890.4% | -1,074.6% |
| Other Income/Exp. Net | $2,019,022 | -$20,503 | -$16,106 | -$5,202 |
| Pre-Tax Income | $1,687,574 | -$239,724 | -$145,223 | -$81,766 |
| Tax Expense | $2 | $3 | $3 | $2 |
| Net Income | $1,687,572 | -$241,361 | -$145,226 | -$81,768 |
| % Margin | 843,786% | -13,408.9% | -6,625.3% | -1,147.6% |
| EPS | 116.58 | -5.12 | -3.62 | -2.15 |
| % Growth | 2,377% | -41.4% | -68.4% | – |
| EPS Diluted | 116.58 | -5.12 | -3.62 | -2.15 |
| Weighted Avg Shares Out | 14,476 | 47,130 | 40,108 | 38,010 |
| Weighted Avg Shares Out Dil | 14,476 | 47,130 | 40,108 | 38,010 |
| Supplemental Information | – | – | – | – |
| Interest Income | $10,940 | $11,917 | $16,107 | $5,216 |
| Interest Expense | $13,491 | $31,840 | $16,107 | $5,216 |
| Depreciation & Amortization | $2,285 | $1,191 | $1,225 | $1,195 |
| EBITDA | $1,703,350 | -$206,693 | -$125,817 | -$75,369 |
| % Margin | 851,675% | -11,482.9% | -5,739.8% | -1,057.8% |